surmount tirzepatide trials ESC 2025: post-hoc SURMOUNT-5 data affirms tirzepatide's lead in CVD risk reduction SURMOUNT-5: Tirzepatide Bests Semaglutide in
Description
A review published in MDPI Biomolecules supports Freya Meds use of GLP-1 treatments, noting that these medications help regulate appetite, promote weight reduction, and improve long-term metabolic balance [2]
Investigational metabolic peptide targeting weight-management and appetite pathways
Regularly monitoring blood sugar levels is also important to detect and treat low blood sugar promptly
It is not a generic version of, and is not the same as, Zepbound or Mounjaro
